These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 18271184

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ, Petraki K, Sfakianakis M, Archavlis E, Christidou A, Chadio-Iordanides H, Triadaphyllou G.
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [Abstract] [Full Text] [Related]

  • 3. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E, International Budesonide-Mesalazine Study Group.
    Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
    [Abstract] [Full Text] [Related]

  • 4. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG, Sandborn WJ.
    Rev Gastroenterol Disord; 2002 Mar; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
    Tromm A, Bunganič I, Tomsová E, Tulassay Z, Lukáš M, Kykal J, Bátovský M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Stimac D, Schäffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R, International Budenofalk Study Group.
    Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
    [Abstract] [Full Text] [Related]

  • 7. [New therapeutic modalities in Crohn's disease].
    Rachmilewitz D.
    Harefuah; 1999 Jun 15; 136(12):943-5. PubMed ID: 10955155
    [No Abstract] [Full Text] [Related]

  • 8. [Prevention of post-operative recurrence in Crohn's disease: a critical review of randomized controlled trials and meta-analyses of different therapeutic strategies].
    Margagnoni G, Clemente V, Aratari A, Fascì Spurio F, De Gregorio AM, Spagnolo A, Koch M, Papi C.
    Recenti Prog Med; 2013 Apr 15; 104(4):168-76. PubMed ID: 23748641
    [Abstract] [Full Text] [Related]

  • 9. Review article: prevention of postsurgical relapse and recurrence in Crohn's disease.
    Cottone M, Orlando A, Viscido A, Calabrese E, Cammà C, Casà A.
    Aliment Pharmacol Ther; 2003 Jun 15; 17 Suppl 2():38-42. PubMed ID: 12786611
    [Abstract] [Full Text] [Related]

  • 10. Treatment of Crohn's disease at the turn of the century.
    Bickston SJ, Cominelli F.
    N Engl J Med; 1998 Aug 06; 339(6):401-2. PubMed ID: 9691110
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term outcome of surgically treated Crohn's colitis: a prospective study.
    Fichera A, McCormack R, Rubin MA, Hurst RD, Michelassi F.
    Dis Colon Rectum; 2005 May 06; 48(5):963-9. PubMed ID: 15785882
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Budesonide for Crohn's disease.
    Seow CH, Benchimol EI, Steinhart AH, Griffiths AM, Otley AR.
    Expert Opin Drug Metab Toxicol; 2009 Aug 06; 5(8):971-9. PubMed ID: 19611401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.